Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)

Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)

Objectives: Fluvoxamine (FVX) is an antidepressant proposed to its immunomodulatory effects in preventing deterioration in mild and moderate COVID-19. Methods: An open-label, 1:1 randomized controlled trial was assigned either combination therapy 50 mg twice daily of FVX for 10 days and favipiravir...

Full description

Bibliographic Details
Main Authors: Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai, Tararin Nimmol, Mullika Buttakosa, Gaidganok Sornsamdang, Tanadul Jarrusrojwuttikul, Phumin Silapant, Nithi Mahanonda
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:International Journal of Infectious Diseases
Subjects:
Fluvoxamine
Favipiravir
COVID-19
SARS-CoV-2
SSRI
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223006410

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223006410

Similar Items